Arthroscopic Surgery Unit, Orthopaedic Surgery Department, Cangzhou Central Hospital, Cangzhou Shi, Hebei Province, 061001, China.
Blood Test Unit, Laboratory Department, Cangzhou Central Hospital, Cangzhou Shi, Hebei Province, China.
Clin Rheumatol. 2018 May;37(5):1341-1350. doi: 10.1007/s10067-018-3985-6. Epub 2018 Jan 31.
The aim of this study was to evaluate the benefit provided by intraosseous infiltration combined with intra-articular injection of platelet-rich plasma to treat mild and moderate stages of knee joint degeneration (Kellgren-Lawrence score II-III) compared with other treatments, specifically intra-articular injection of PRP and of HA. Eighty-six patients with grade II to grade III knee OA according to the Kellgren-Lawrence classification were randomly assigned to intra-articular combined with intraosseous injection of PRP (group A), intra-articular PRP (group B), or intra-articular HA (group C). Patients in group A received intra-articular combined with intraosseous injection of PRP (administered twice, 2 weeks apart). Patients in group B received intra-articular injection of PRP every 14 days. Patients in group C received a series of five intra-articular injections of HA every 7 days. All patients were evaluated using the Visual Analogue Scale (VAS) and Western Ontario and McMaster Universities (WOMAC) score before the treatment and at 1, 3, 6, 12, and 18 months after treatment. There were significant improvements at the end of the 1st month. Notably, group A patients had significantly superior VAS and WOMAC scores than were observed in groups B and C. The VAS scores were similar in groups B and group C after the 6th month. Regarding the WOMAC scores, groups B and C differed at the 1st, 3rd, 6th, and 12th months; however, no significant difference was observed at the 18th month. The combination of intraosseous with intra-articular injections of PRP resulted in a significantly superior clinical outcome, with sustained lower VAS and WOMAC scores and improvement in quality of life within 18 months.
本研究旨在评估与其他治疗方法相比,骨内渗透联合关节内注射富血小板血浆(PRP)治疗膝关节轻中度退变(Kellgren-Lawrence 分级 II-III)的益处,特别是关节内注射 PRP 和 HA。86 例膝关节 OA 患者按 Kellgren-Lawrence 分级为 II 至 III 级,随机分为关节内联合骨内注射 PRP(A 组)、关节内 PRP(B 组)和关节内 HA(C 组)。A 组患者接受关节内联合骨内注射 PRP(2 次,间隔 2 周)。B 组患者每 14 天接受一次关节内注射 PRP。C 组患者每 7 天接受一次连续 5 次关节内注射 HA。所有患者在治疗前和治疗后 1、3、6、12 和 18 个月时均采用视觉模拟评分(VAS)和西部安大略省和麦克马斯特大学(WOMAC)评分进行评估。治疗后第 1 个月即有显著改善。值得注意的是,A 组患者的 VAS 和 WOMAC 评分明显优于 B 组和 C 组。治疗后第 6 个月,B 组和 C 组的 VAS 评分相似。关于 WOMAC 评分,B 组和 C 组在第 1、3、6 和 12 个月时存在差异;然而,在第 18 个月时没有观察到显著差异。骨内联合关节内注射 PRP 可显著改善临床疗效,18 个月内 VAS 和 WOMAC 评分持续较低,生活质量改善。